Clinical Trial Update: Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 trial update for CMX001 in preventing or controlling cytomegalovirus infection in CMV-seropositive hematopoietic stem cell transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• CMX001 (brincidofovir)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Cytomegalovirus Infection | Phase 2 | Status: COMPLETED | Results posted: 2021-07-16